[Mantle cell lymphoma: case report].
Mantle cell lymphoma (MCL) is a moderately aggressive disease, which is not curable with chemo-immunotherapy. The median survival duration is short, approximately three years. Most of the patients have advanced stage disease at the time of diagnosis. Fifty percent of the patients show infiltration of the bone marrow, in 25% of the MCL patients the gastrointestinal tract is involved, in 25% of patients leukaemic transformation occurs. The tumor cells express pan-B-cell markers and the T-cell marker CD5. The overexpression of cyclin D1 was found as another marker for mantle cell lymphoma. Combined chemotherapy, chemo-immunotherapy, autologous peripheral stem cell (and allogenous) transplantation is the treatment of choice. Our two patients had prolonged survival, in spite of missing the best first line therapy. The survival time after the complex treatment (chemo-immunotherapy, irradiation, surgical intervention, autologous stem cell transplantation) was 80 and 90 months, respectively. In addition to the history of two patients, authors review the current treatment options in mantle cell lymphoma.
Méhes
Leonóra
L
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Belgyógyászati Intézet, II. Belgyógyászati Klinika, Hematológiai Tanszék, Debrecen Nagyerdei krt. 98. 4032. mehes_leonora@yahoo.com
Telek
Béla
B
Udvardy
Miklós
M
Schlammadinger
Agota
A
és Rejto
László
L
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome